| 9.68 -1.26 (-11.52%) | 05-21 15:39 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 12.36 |
1-year : | 13.13 |
| Resists | First : | 10.58 |
Second : | 11.24 |
| Pivot price | 10.46 |
|||
| Supports | First : | 9.51 |
Second : | 7.91 |
| MAs | MA(5) : | 10.51 |
MA(20) : | 10.32  |
| MA(100) : | 8.94 |
MA(250) : | 7.76 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 53.1 |
D(3) : | 61.9 |
| RSI | RSI(14): 43.6 |
|||
| 52-week | High : | 11.24 | Low : | 5.8 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ BVS ] has closed below the lower bollinger band by 6.3%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ BVS ] is to continue within current trading range. Bollinger Bands are 25.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 11.01 - 11.06 | 11.06 - 11.1 |
| Low: | 10.44 - 10.49 | 10.49 - 10.54 |
| Close: | 10.86 - 10.94 | 10.94 - 11.01 |
Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies include an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.
Thu, 21 May 2026
Is Bioventus (BVS) Stock Undervalued Right Now? - Yahoo Finance
Mon, 18 May 2026
Are Medical Stocks Lagging Bioventus (BVS) This Year? - Yahoo Finance
Fri, 15 May 2026
Statutory Profit Doesn't Reflect How Good Bioventus' (NASDAQ:BVS) Earnings Are - Sahm
Thu, 07 May 2026
Bioventus (BVS) Reports Strong Q1 Revenue Growth - GuruFocus
Wed, 06 May 2026
Bioventus: Q1 Earnings Snapshot - kens5.com
Wed, 06 May 2026
Bioventus (BVS) lifts 2026 EPS outlook after Q1 revenue and cash-flow gains - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 68 (M) |
| Shares Float | 34 (M) |
| Held by Insiders | 11.2 (%) |
| Held by Institutions | 78.2 (%) |
| Shares Short | 1,470 (K) |
| Shares Short P.Month | 1,530 (K) |
| EPS | 0.4 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.78 |
| Profit Margin | 4.9 % |
| Operating Margin | 6.7 % |
| Return on Assets (ttm) | 5.6 % |
| Return on Equity (ttm) | 16.4 % |
| Qtrly Rev. Growth | 6.5 % |
| Gross Profit (p.s.) | 5.84 |
| Sales Per Share | 8.5 |
| EBITDA (p.s.) | 1.19 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 103 (M) |
| Levered Free Cash Flow | 63 (M) |
| PE Ratio | 23.75 |
| PEG Ratio | 1.3 |
| Price to Book value | 3.49 |
| Price to Sales | 1.14 |
| Price to Cash Flow | 6.41 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|